Mazen Animal Health, an animal health company developing maize-based vaccines, announced it has been issued a patent from the U.S. Patent and Trademark Office for its technology to produce orally delivered animal vaccines. The patent covers foundational technology for the company’s first vaccine product for Porcine Epidemic Diarrhea Virus, according to a news release. The virus is a widespread concern with a death rate of 80% to 100% in infected piglets. Prevention in neonatal pigs is difficult because the virus is highly infectious and able to survive in the environment even with strict sanitation practices. The release said Mazen’s vaccine product is anticipated to launch in 2024.
